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Background: Human Papillomavirus (HPV) is the most common sexually transmitted infection. The main risk factors
correlated with HPV infection are: early sexual debut, the number of partners, frequency and type of sexual contact
and partner’s sexual histories.
We surveyed sexual habits among young people in order to provide information that might orient decision-makers
in adopting HPV multi-cohort vaccination policies.
Methods: We administered a questionnaire to students (14–24 years old) in five Italian cities.
Results: 7298 questionnaires were analyzed (4962 females and 2336 males); 55.3% of females (95% CI 53.9–56.7)
and 52.5% of males (95% CI 50.5–54.5) reported regular sexual activity. The mean age at sexual debut was 15.7 ± 1.6
and 15.6 ± 1.6 for females and males, respectively, and the median age was 16 for both sexes.
With regard to contraceptive use during the last year, 63.6% of males and 62.8% of females responded affirmatively;
42.6% of males and 42.8% of females used condoms.
Conclusion: The results reveal precocious sexual activity among respondents, with the mean age at first intercourse
declining as age decreases. Condom use proved to be scant. Considering lifestyle-related risk factors, males appear
to have a higher probability of acquiring HPV infection than females.
These data support the importance of promoting multi-cohort HPV vaccination strategies for females up to 25 years
of age. It is essential to improve vaccination coverage through different broad-spectrum strategies, including
campaigns to increase awareness of sexually transmitted diseases and their prevention.
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Human Papillomavirus (HPV) is one of the most com-
mon sexually transmitted infections in sexually active
adolescents and young people worldwide. HPV is gener-
ally spread through sexual contact [1] and direct skin-
to-skin contact, the most common route of transmission
being through penetrative sex [2].
All sexually active men and women are susceptible to
acquiring genital HPV infection. The life-time risk of
HPV infection is up to 80%. Most of these infections (up
to 90%) are cleared within 2 years (12–24 months) and
only a few become persistent [3]. The first HPV infec-
tion often occurs soon after the first sexual intercourse
(FSI), the cumulative rate of genital HPV infection being
approximately 50% over 3 years after the first inter-
course [4,5]. The prevalence of HPV infection is highest
among young women (18–24 years) soon after the onset
of sexual activity, and falls gradually with age until the
4th-5th decade, when a second peak occurs for hormo-
nal changes during perimenopause, followed by another
decline [6]. Young subjects are exposed to HPV infec-
tion more often because of their sexual behaviour, and
young women are more vulnerable than older women
because the transformation zone is located on the ecto-
cervix (cervical ectopy) [7].
The likelihood of developing precancerous lesions
increases with persistent infections [8]. Persistent infec-
tion with an oncogenic type of HPV is a prerequisite to
developing cervical cancer [9] and can determine cancer
in other anatomical sites, such as the anus, vagina, vulva,
oral cavity and oropharynx [10,11].
The most frequent risk factors correlated with the in-
fection and persistence of HPV in the population are the
following: initiation of sexual activity at a young age, the
number of life-time sexual partners, frequency of sex or
other intimate skin-to-skin contact, the sexual histories
and behaviours of sexual partners, cigarette smoking,
parity, the use of some types of oral contraceptives and
alcohol consumption [2].
It is known that, among 150 different HPV types, only
about 60 are able to infect the ano-genital area and that
vaccination is a useful tool for preventing HPV infection
caused by types more frequently involved [12–17]. For
some years, two HPV vaccines have been on the market
in Europe (EU): a quadrivalent vaccine (GardasilW),
licensed in September 2006, and a bivalent vaccine (Cer-
varixW), licensed in September 2007. Both vaccines have
a prophylactic indication and are able to prevent pre-
cancerous lesions (CIN II +) and cancers due to persist-
ent infection with HPV-16 or HPV-18. Furthermore,
both vaccines have been shown to elicit cross-protection
against other high-risk HPV types [13–17]. GardasilW
also offers protection against genital warts caused by
HPV-6 and HPV-11.As HPV infection is exclusively contracted through
sexual activity, it was recommended that adolescent
females should be vaccinated against HPV before their
sexual debut, as the main target population. Therefore,
in March 2008, the Italian Ministry of Health recom-
mended that regional authorities should start a cam-
paign of free HPV vaccination for 12-year-old girls [18].
Since the introduction of HPV vaccination, many studies
have been conducted with the aim of helping decision-
makers choose the best vaccination policy [19–24].
Another important issue concerns the coverage rate,
since only by achieving high coverage can circulation of
the virus be rapidly reduced, thereby exerting a greater
impact on diseases related to HPV genotypes. Indeed, in
its HPV immunization plan, the Italian Ministry of
Health has set the goal of achieving 95% coverage within
5 years of initiating the vaccination program in 12-year-
old girls [18].
As many studies [2,25,26] of HPV prevalence and inci-
dence indicate that the most consistent predictor of in-
fection is sexual activity, particularly age on first
intercourse and the number of sexual partners, we car-
ried out a study of sexual habits among young people in
Italy in order to provide information that might orient
decision-makers in the choice of a multi-cohort vacci-
nation policy; indeed, knowing the age of onset of sexual
activity is essential to guiding Regional Health Authority
recommendations regarding the optimal age for prophy-
lactic HPV vaccination. The study did not envisage col-
lecting data on vaccination acceptance.
Methods
The study was approved by Ethic Committee of the
Genoa Local Healthcare Unit, Italy (Azienda Sanitaria
Locale 3 Genovese).
The study was carried out from May 2008 to May
2011.
Questionnaire
We administered an ad hoc written questionnaire in
order to survey the sexual behaviour and risk factors for
HPV infections among young students (14–24 years old)
in five Italian cities: Genoa, Florence, Turin, Cagliari and
Sassari. The questionnaire comprised 20 questions co-
vering the following specific items: demographics, level
of education, sexual activity (penetrative genital-genital
sex), age at first sexual intercourse, and sexual behaviour
in terms of the number of sexual partners and contra-
ceptive use (Additional file 1). The definition of regular
sexual activity was to have sexual intercourse two or
more times a month [27].
It took about 20 minutes to answer the self-
administered questionnaire. In order to encourage open-
ness and honesty in the answers, confidentiality and
Panatto et al. BMC Public Health 2012, 12:623 Page 3 of 9
http://www.biomedcentral.com/1471-2458/12/623secrecy were assured by avoiding any questions regard-
ing the identity of the respondents. During completion
of the questionnaires, communication among the
respondents was practically impossible, as the students
were seated at a considerable distance from one another
in spacious rooms. These precautions were taken in
order to minimise the known limitations, and thus po-
tential information bias, of self-reporting methods.
Trained physicians were on hand to explain the ques-
tions, if necessary.
Before initiation of the study, the questionnaire was
pilot tested on 50 Ligurian students, in order to evaluate
the comprehension and relevance of our terms. As no
problems were identified, the questionnaire was used in
the study.
All questionnaires were checked on the basis of quality
control (e.g. for internal coherence of the questionnaire).
Study population
A representative sample ranging between 15% to 20% of
secondary schools (high-schools, technical schools and
vocational schools) located in the five above-mentioned
cities participated in the study; these were randomly
selected. A stratified sampling technique was used and
strata were detected by age group (14–16 years, 17–19
and 20–24 years) and gender. From each school, about
10% of the students were interviewed. Furthermore, a
random sample of university students (20-24-year age-
group) stratified by gender was chosen from a list of
those enrolled in the Universities of Genoa, Florence,
Turin, Cagliari and Sassari.
As the primary target for vaccination against HPV is
the female population, we recruited a higher number of
females than males (2:1) in the study.
Risk-groups
The subjects enrolled, independently of their age at the
moment of filling in the questionnaire, were classified by
risk-group in terms of their probability of acquiring
HPV infection. The risk-groups were drawn up on the
basis of literature data [28]. However, as no precise sys-
tem of classifying subjects into risk groups is available in
the literature, we distributed subjects on the basis of the
following risk factors: age at first intercourse and lifetime
sexual partners.
The low-risk group included subjects who had had
only one partner in their life, regardless of their age at
sexual debut, and those who had had 2 partners but had
first experienced intercourse at > 15 years of age.
The medium-risk group comprised subjects who had
had 2 partners and had begun sexual activity before the
age of 15 years. This group also included subjects who
had had 3 partners but whose sexual activity had begun
at the age of ≥ 15 years.Subjects reporting 3 partners and a sexual debut be-
fore the age of 14 years, and all subjects reporting ≥ 4
partners, regardless of age at sexual debut, were assigned
to the high-risk group.Statistical analysis
Statistical analysis was performed by means of Statpages
(Technical University of Denmark) [29], Openepi ver-
sion 2.3.1 (Open Source Epidemiologic Statistics for
Public Health) [30], Excel version 2011 14.1.3 (Microsoft
Corporation – Redmond, Washington) and R (Develop-
ment Core Team 2011) [31] software.
Differences between proportions were compared by
means of z-test. Categorical variables were compared by
Chi-square test and continuous variables by ANOVA.
Variation across levels of single binomial proportions
was tested by means of Chi-square test for trend. A
p-value of ≤0.05 was considered statistically significant.Results
A total of 7500 students were invited to participate in
the study; 51 declined. As few students refused to par-
ticipate in the study, the reasons for refusal were not
investigated.
The study involved 7449 volunteers aged 14–24 years
(2386 males and 5063 females). We excluded 151 ques-
tionnaires from the analysis on the basis of quality con-
trol. Thus, 7298 questionnaires were analyzed (4962
females and 2336 males).
Out of 7298 subjects studied, 3334 (2222 females and
1112 males) were in the 14-16-year age-group, 2784
(1908 females and 876 males) were aged between 17 and
19 years, and 1180 (7832 females and 348 males)
belonged to the 20–24 year age-group. Out of 7298 sub-
jects studied, 6861 (4659 females and 2202 males) were
Italians and 437 (303 females and 134 males) were
foreigners.
Since the answers of the foreign students did not differ
from those of the Italian students, a combined statistical
analysis was performed. Likewise, as no statistically sig-
nificant differences emerged among the answers given
by the students from the five Italian cities, this statistical
analysis was also combined.
A total of 55.3% of females (95% CI 53.9 – 56.7) and
52.5% of males (95% CI 50.5 – 54.5) reported regular
sexual activity. No statistically significant differences
were found on considering gender.
The study considered only subjects who declared regu-
lar sexual activity after their sexual debut. However, 21
females and 15 males who declared having had a sexual
debut reported irregular sexual activity. These volunteers
have been included in the group of subjects “NO regular
sexual activity” (Table 1).
Table 1 Regular sexual activity of enrolled subjects, age at sexual debut and subjects with regular sexual activity prior
15th birthday by gender and age-group
Regular sexual activity** of enrolled subjects
SEXUAL ACTIVITY FEMALES MALES
Age-group (years) Age-group (years)
14-16 17-19 20-24 14-16 17-19 20-24
YES, N°(%), 689 (31.0) 1316 (69.0) 741 (89.1) 337 (30.3) 594 (67.8) 296 (85.0)
95% CI 29.1- 32.9 66.8 - 70.9 86.9 - 91.2 27.6 - 33.0 64.6 - 70.8 81.2 -88.7
NO, N°(%) 1414 (63.6) 485 (25.4) 65 (7.8) 645 (58.0) 203 (23.2) 26 (7.5)
95% CI 61.6 - 65.6 23.4 - 27.3 5.9 - 9.6 55.1 - 60.9 20.4 - 25.9 4.7 – 10.3
NR** , N°(%) 119 (5.4) 107 (5.6) 26 (3.1) 130 (11.7) 79 (9.0) 26 (7.5)
Age at sexual debut
Mean± SD 15.7 ± 1.6 15.6 ± 1.6
Median 16 16
(25th -75th P) (15–17) (15–17)
14-16 17-19 20-24 14-16 17-19 20-24
N° 688 1313 738 337 593 291
NR*(1) NR*(3) NR*(3) NR*(0) NR*(1) NR*(5)
Mean 14.5 15.7 16.9 14.3 15.8 16.7
SD ±1.0 ±1.3 ±1.8 ±0.9 ±1.3 ±1.7
Median 15 16 17 14 16 17
25th -75th P 14-15 15-17 16-18 14-15 15-17 16-18
Subjects with regular sexual activity** prior to 15th birthday
14-16 17-19 20-24 14-16 17-19 20-24
Sexual debut < 15 year 327 257 60 203 108 26
(47.5%) (19.6%) (8.1%) (60.2%) (18.2%) (8.9%)
(95% CI) (43.8-51.2) (17.4-21.7) (6.1-10.1) (54.9-65.4) (15.1-21.3) (5.6-12.2)
Sexual debut≥ 15 year 361 1056 678 134 485 265
(52.5%) (80.4%) (91.9%) (39.8%) (81.8%) (91.1%)
(95% CI) (48.8-56.2) (78.2-82.5) (89.9-93.9) (34.6-45.0) (78.7-84.9) (87.8-94.4)
* NR = non-responders.
** Definition of regular sexual activity: having sexual intercourse two or more times a month.
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debut by age-group and gender. It also reports the sexu-
ally active subjects who stated regular sexual activity
prior to their 15th birthday. The percentage of subjects
in each age-group who were sexually active before their
15th birthday was calculated in order to better assess the
changes in sexual habits among the young.
With regard to regular sexual activity, a significant
(p < 0.001) increasing trend in proportions by age was
observed in both sexes.
Among females, the mean age at sexual debut was
15.7 ± 1.6 and the median age was 16 (25th and 75th per-
centiles = 15-17). Among males, the mean age at sexual
debut was 15.6 ± 1.6 and the median age was 16 (25th
and 75th percentiles = 15-17).
Comparison of the mean ages at sexual debut among
the age-groups of respondents of the same sex was
carried out by means of analysis of variance (ANOVA).
This revealed a highly significant difference (p < 0.001),
indicating that, among the subjects who declared sexualactivity, younger subjects debuted earlier than their older
counterparts. Most females had their first sexual inter-
course with a partner 2.4 years older, while males first
had intercourse with a partner 0.5 years older (data not
shown).
Table 2 shows the characteristics of sexual behaviour
by gender and age-group among sexually active subjects.
The number of lifetime sexual partners increases with
age in both sexes, and males report more multiple part-
nerships than females. No difference was found in the
number of partners prior to the respondent’s 15th birth-
day, nor in the number of sexual partners in the last year
among the different age-groups.
Figure 1 reports the numbers and percentages of males
and females, broken down according to the risk of acquir-
ing HPV infection. Among males, 434 (38.2% 95%CI 35.8-
40.5), 232 (20.4% 95%CI 18.4-22.3) and 470 (41.4% 95%CI
39.9-43.8) subjects fell into the low-risk, medium-risk and
high-risk groups, respectively. Among females, 1479
(55.0% 95%CI 53.1-56.9), 524 (19.5% 95%CI 18.0-20.9)
Table 2 Characteristics of sexual behaviour by gender and age-group among respondents who declared sexual activity
FEMALES MALES
Age-group (years) 14-16 17-19 20-24 14-16 17-19 20-24
Age of first sexual partner (years)
N° 668 1293 732 330 575 286
(NR* = 21) (NR* = 23) (NR* = 9) (NR* = 7) (NR* = 19) (NR* = 10)
Mean age 17.1 18.3 19.5 15.0 16.1 17.2
SD 2.2 2.73 3.43 1.67 2.39 3.07
Range 12-36 12-38 13-39 11-22 11-38 11-37
Lifetime sexual partners (number)
N° 668
(NR* = 21)
1288
(NR* = 28)
733
(NR* = 8)
312
(NR* = 25)
548
(NR* = 46)
277
(NR* = 19)
Median 1 2 2 2 3 3
25th-75th P 1-2 1-3 1-4 1-3.75 1-5 2-7
Range 1-30 1-32 1-50 1-27 1-27 1-32
Sexual partners prior to 15th birthday (number)
N° 319
(NR* = 8)
255
(NR* = 2)
60
(NR* = 0)
192
(NR* = 11)
105
(NR* = 3)
25
(NR* = 1)
Median 1 1 1 1 2 1
25th -75th P 1-2 1-2 1-2 1-3 1-3 1-3
Range 1-20 1-15 1-15 1-16 1-10 1-5
Sexual partners in the last year (number)
N° 666
(NR* = 23)
1286
(NR* = 30)
736
(NR* = 5)
324
(NR* = 13)
571
(NR* = 23)
282
(NR* = 14)
Median 1 1 1 1 1 1
25th-75th P 1-1 1-1 1-1 1-2 1-2 1-2
Range 1-10 1-19 1-13 1-21 1-15 1-15
* NR = non-responders.
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low-risk, medium-risk and high-risk groups, respectively.
Table 3 shows the percentage of subjects who used a
contraceptive method during their sexual debut byAge at sexual debut
MALE
N° (%) 1 2
N° (%) N° (%
11 4 (0.3)
12 17 (1.4) 2 (0.
13 61 (5.0) 8 (0.6) 10 (0
14 255 (20.8) 68 (5.5) 38 (3
15 261 (21.3) 58 (4.7) 50 (4
> 15 623 (50.8) 195 (15.9) 105 (8
NR* 241
FEMAL
11 3 (0.1)
12 26 (0.9) 3 (0.
13 129 (4.7) 24 (0.9) 25 (0
14 486 (17.7) 162 (5.9) 93 (3
15 686 (25.0) 287 (10.4) 143 (
> 15 1384 (50.4) 690 (25.1) 316 (1
NR* 260
Green = low risk, yellow = medium risk, red = high risk 
* NR = non-responders 
Figure 1 Number of males and females in the various HPV risk-groupgender and age-group. Overall, the use of a contracep-
tive method at sexual debut was reported by 62.2% (95%
CI 59.5-64.9) of males; 58.9% (95% CI 56.1-61.6) indi-
cated using a condom. Among females, 70.3% (95% CILifetime sexual partners
S
3 ≥ 4 NR*
) N° (%) N° (%)
1 (0.1) 3 (0.2) 0
2) 1 (0.1) 14 (1.1) 0
.8) 6 (0.5) 30 (2.4) 7
.1) 27 (2.2) 114 (9.3) 8
.1) 41 (3.3) 90 (7.3) 22
.6) 91 (7.4) 184 (15.0) 48
ES
3 (0.1) 0
1) 2 (0.1) 19 (0.7) 2
.9) 23 (0.8) 54 (1.9) 3
.4) 70 (2.5) 158 (5.7) 3
5.2) 91 (3.3) 148 (5.4) 17
1.5) 169 (6.1) 209 (7.6) 24
s.
Table 3 Use of a contraceptive method during first intercourse and during last year among respondents who declared
sexual activity by gender and age-group
FEMALES MALES
Use of a contraceptive method at sexual debut
Age-group (years) Age-group (years)
14-16 17-19 20-24 14-16 17-19 20-24
YES* , N°(%) 447/689
(64.9)
914/1316
(69.4)
571/741
(77.0)
183/337
(54.3)
398/594
(67.0)
182/296
(61.4)
95% CI 61.3-68.7 66.9-71.9 74.0-80.0 49.0-59.6 63.7-70.3 55.9-66.9
YES CONDOM,
N°(%)
435/689
(63.1)
870/1316
(66.1)
541/741
(73.0)
178/337
(52.8)
372/594
(62.6)
173/296
(58.4)
95% CI 59.5-66.7 63.5-68.7 69.8-76.2 47.5-58.1 58.7-66.5 52.8-64.0
NR**, N°(%) 68/689 (9.9) 112/1316
(8.5)
90/741
(12.1)
41/337
(12.2)
76/594
(12.8)
40/296
(13.5)
Use of a contraceptive method during last year
14-16 17-19 20-24 14-16 17-19 20-24
YES* + , N°(%) 324/543 850/1223 375/700 132/265 369/524 171/267
(59.6) (69.5) (53.5) (49.8) (70.4) (64.0)
95% CI 55.5-63.7 66.9-72.1 49.8-57.2 43.8-55.8 66.5-74.3 58.2-69.7
YES + CONDOM,
N°(%)
244/543 554/1223 257/700 91/265 244/524 115/267
(45.0) (45.3) (36.7) (34.3) (46.5) (43.0)
95% CI 40.8-49.2 42.5-48.1 33.1-40.3 28.6-40.0 42.2-50.8 37.1-48.9
YES PILL, N°(%) 66/543 300/1223 157/700
(12.1) (24.5) (22.4)
95% CI 9.3-14.8 22.1-26-9 19.3-25.5
NR**, N°(%) 63/543
(11.6)
106/1223
(8.7)
126/700
(18.0)
64/265
(24.1)
68/524
(13.0)
39/267
(14.6)
* condom, pill, coitus interruptus.
** NR= non-responders.
+ every time, almost every time.
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ual debut; 67.2% (95% CI 65.9-69.3) specified using a
condom. Moreover, a significant (females: p < 0.001;
males: p < 0.05) increasing trend in proportions of the
use of contraceptive methods by age was observed in
both sexes.
With regard to the use of contraceptive methods dur-
ing the last year, 63.6% (95% CI 60.7-66.5) of males
responded affirmatively, and 42.6% (95% CI 39.6-45.6)
reported using a condom. Among females, 62.8% (95%
CI 60.9-64.7) responded affirmatively: 42.8% (95% CI
40.8-44.7) reported using a condom and 21.2% (95% CI
19.6-22.8) oral contraception.
With regard to the use of a contraceptive method dur-
ing the last year by gender and age-group, an increasing
trend (p < 0.05) was observed by age for males (Table 3).
Discussion
This paper reports the results of a study of self-reported
sexual behaviour in adolescents and young people aged
14–24 years in Italy.
More than two thirds of the students involved in this
study were females, who constitute the target populationof HPV vaccination. The results yielded by this sample
therefore enabled the suitability of the current vaccine-
tion strategies in Italy to be evaluated indirectly, in that
sexual activity is the most consistent predictor of the
probability of acquiring HPV infection.
Exposure to HPV infection is determined by risks fac-
tors such as an early sexual debut, a high number of life-
time sexual partners, a high number of recent or current
sexual partners and the sexual histories and behaviours
of sexual partners [2,25]. Condom use has a protective
effect, although its effectiveness in reducing HPV acqui-
sition has not been completely clarified [32,33].
The results of our study highlight the early start of sex-
ual activity among young students in Italy, with a mean
age at sexual debut of 15.7± 1.6 for females and 15.6± 1.6
for males. No statistically significant differences were
found on considering gender and the city of residence. In
recent years, lifestyle changes, especially in sexual behav-
iour, have been registered among adolescents in Europe
[25,34]. Young people travel a lot and have more open
and changeable interpersonal relationships. We noted a
decrease in the mean age at first intercourse on compar-
ing the various age-groups of the subjects (Table 2);
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tive females and 60.2% of the sexually active males
reported having their first sexual intercourse before their
15th birthday, and a third of the interviewees aged 14–
16 years old declared that they already indulged in regular
sexual activity.
Most of the females stated that their sexual debut was
with a partner 2.4 years older, while the males reported
their first intercourse with a partner of the same age. As
the sexual behaviour of the partner, particularly the
number of previous sexual partners, is a risk factor for
the transmission of mucosal HPV infection, having an
older partner increases the probability of acquiring the
virus. Consequently, females could have a higher risk
than males at sexual debut.
The number lifetime sexual partner increases with age,
and males report more multiple partnerships than females.
On the basis of age at sexual debut and the number of
lifetime sexual partners, the respondents were grouped
into different risk-group. Considering lifestyle-related
risk factors, males appear to have a higher probability of
acquiring HPV infection than females. Indeed, more
males fell into the high-risk group (41.4%) than the low-
(38.2%) or medium-risk groups (20.4%), while most
females were in the low-risk group (55.0%). The exact
probability of transmission through sexual contact or
partnership is not precisely known. Barnabas et al. esti-
mated a value of transmission probability using a math-
ematical modelling analysis. They considered that the
transmission probability could varied between 0 to 1,
and they found that the probability of transmission was
approximately 0.4 for annual partner change rate [28].
Burchell et al. report a partnership transmission prob-
ability of 0.20; they observe little difference in the rate of
male-to-female (3.5 transmissions per 100 person-
months) versus female-to-male transmission (4.0 trans-
missions per 100 person-months) [35]. Other studies
have found higher rates of female-to-male than male-to-
female transmission [36–38].
Our data indicate a low use of condoms. With regard to
regular condom use during the last year, no difference be-
tween the genders emerged. In the female group, however,
we noted statistically significant differences (p< 0.05) be-
tween age-groups. The percentage of females who regu-
larly use condoms was seen to decline as age increased, in
particular in the 20–24 age-group. This could be
explained by the fact that older females reported more
stable and durable relationships and a greater use of the
pill. We surmise, also on the basis of literature data
[39,40], that many young people use condoms to prevent
unwanted pregnancies, but that they have scant know-
ledge or perception of the risk of sexually transmitted
infections. In the male group, the percentage of students
who regularly use condoms increased with increasing age.Direct comparison of our results with data from other
studies conducted in Italy and other European countries
is complicated by the different methodologies used and
the different populations monitored. A study published
in 2006 reported data on sexual behaviour in 59 coun-
tries worldwide during the period 1996–2006. The
authors found median ages at sexual debut of 17.5 and
18.5 years among young men and women, respectively,
in Italy. The difference between these findings and those
of our study can be attributed to the cohorts of the sub-
jects interviewed; our students were born between 1984
and 1996, while those of Wellings’ study were born be-
tween 1965 and 1969 [41]. This confirms a lifestyle
change in recent years. In a survey conducted in 2006–
2007 in 7 European countries, Crochard et al. reported a
median age at sexual debut of 16 and 17 for males and
females, respectively, in Italy [25]. Our research group
carried out an investigational study on sexual behaviours
among adolescents in a Region of Northern Italy from
2006 to 2007, and found similar results [42].Conclusions
These data confirm the importance of promoting multi-
cohort HPV vaccination strategies for young females. The
strategy of free vaccination for females up to 25 years of
age in Italy appears advantageous. This approach would
rapidly reduce circulation of the virus and, consequently,
have a greater impact on diseases related to HPV geno-
types at high oncogenic risk.
Furthermore, it is essential to make every effort to im-
prove the coverage of HPV vaccination. Indeed, data on
coverage in Italy (updated as of 30th June 2011) revealed a
coverage rate of 65% for the primary target of vaccination
(12-year-old girls); since the beginning of the immunization
program, no improvement has yet been observed [43]. To
this end, it is necessary to implement a range of broad-
spectrum strategies, including communication campaigns
to increase awareness of sexually transmitted infections and
their prevention. Teenagers’ sexual behaviours have both
short-term and long-term consequences, and interventions
that focus on this target population may be the most effect-
tive in helping to promote overall health among young
adults.
Information campaigns can only be successful if they
reach their target populations. In the present case, as
our target population is that of young people, we should
exploit the means of communication which they them-
selves use, such as social networks (facebook, twitter)
and websites dedicated to the young (information on-
line). To achieve high coverage rates of anti-HPV vaccin-
ation, these channels of communication have been
utilised in the United Kingdom, where very good results
have been obtained within a short time [44].
Panatto et al. BMC Public Health 2012, 12:623 Page 8 of 9
http://www.biomedcentral.com/1471-2458/12/623Finally, it is very important that everybody understand
that safe and efficacious vaccines for the prevention of
cervical cancer are available and provide important indi-
vidual and public benefits.
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